LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

Strona główna・Stock List・Altimmune Inc

Altimmune Inc

Closed

4.46 -1.76

Buy Sell

Overview

Share price change

24h

Current

Min

4.38

Max

4.54

Key metrics
By Trading Economics
Income	3.1M -19M
Sales	5K
Profit margin	-380,280
Employees	59
EBITDA	4.4M -18M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+185.09% upside

Dividends
By Dow Jones
Next Earnings	5 mar 2026

Market Stats
By TradingEconomics
Market Cap	217M 566M
Previous open	6.22
Previous close	4.46

Technical Score

By Trading Central

Confidence

Bullish Evidence

5.365 / 6.0486 Support & Resistance

Altimmune Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 lut 2026, 22:04 UTC

Earnings

Coles 1st Half Net Profit Falls 11% on Worker Remediation Costs

26 lut 2026, 23:55 UTC

Market Talk

Gold Edges Higher as Traders Digest U.S.-Iran Talks -- Market Talk

26 lut 2026, 23:40 UTC

Acquisitions, Mergers, Takeovers

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- Update

26 lut 2026, 23:37 UTC

Market Talk

Japanese Stocks May Fall, Tracking Wall Street's Decline -- Market Talk

26 lut 2026, 23:32 UTC

Earnings

Why Nvidia's Huge Numbers Don't Settle the Latest AI Fears -- Heard on the Street -- WSJ

26 lut 2026, 23:19 UTC

Acquisitions, Mergers, Takeovers

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26 lut 2026, 23:18 UTC

Acquisitions, Mergers, Takeovers

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26 lut 2026, 23:12 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

26 lut 2026, 23:12 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Netflix Gives Up in Bidding War Over Warner -- Market Talk

26 lut 2026, 23:01 UTC

Acquisitions, Mergers, Takeovers

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26 lut 2026, 23:00 UTC

Acquisitions, Mergers, Takeovers

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26 lut 2026, 23:00 UTC

Acquisitions, Mergers, Takeovers

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26 lut 2026, 22:55 UTC

Acquisitions, Mergers, Takeovers

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26 lut 2026, 22:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

26 lut 2026, 22:43 UTC

Market Talk

RBA Hike In March Is Being Underpriced -- Market Talk

26 lut 2026, 22:33 UTC

Acquisitions, Mergers, Takeovers

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26 lut 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26 lut 2026, 22:13 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Bidding War Over Warner Bros. Set to Continue -- Market Talk

26 lut 2026, 21:59 UTC

Earnings

D-Wave Quantum Stock Rises on Earnings. Why a Revenue Miss Doesn't Seem to Matter. -- Barrons.com

26 lut 2026, 21:58 UTC

Acquisitions, Mergers, Takeovers

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26 lut 2026, 21:49 UTC

Earnings

Coles 1H Net Profit Falls 11% on Worker Remediation Costs

26 lut 2026, 21:45 UTC

Earnings

Coles Expects One-Off Costs of Around A$7 Million in 1H to Complete Simplification Process

26 lut 2026, 21:44 UTC

Earnings

Coles Says Liquor Sales Fell 2.5% in First Seven Weeks of 3Q

26 lut 2026, 21:44 UTC

Earnings

Coles Expects Market to Remain Highly Competitive

26 lut 2026, 21:44 UTC

Earnings

Coles Says Supermarket Customers Remain Value Oriented

26 lut 2026, 21:43 UTC

Earnings

Coles Says Supermarket Sales Revenue Up 5.3% in First Seven Weeks of 3Q When Tobacco Excluded

26 lut 2026, 21:43 UTC

Earnings

Coles Says Supermarket Sales Revenue Up 3.7% in First Seven Weeks of 3Q

26 lut 2026, 21:42 UTC

Acquisitions, Mergers, Takeovers

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- WSJ

26 lut 2026, 21:41 UTC

Earnings

Acquisitions, Mergers, Takeovers

Warner Bros. Earnings Report Falls Short. What It Means for the Netflix Takeover Saga. -- Barrons.com

Peer Comparison

Price change

Altimmune Inc Forecast

Price Target

By TipRanks

185.09% upside

12 Months Forecast

Average 13 USD 185.09%

High 20 USD

Low 7 USD

Based on 5 Wall Street analysts offering 12 month price targets forAltimmune Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Altimmune Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.365 / 6.0486Support & Resistance

Recent bullish events outweigh bearish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.